Canadian Journal of Infectious Diseases & Medical Microbiology

TABLE OF CONTENTS      November/December 2014 • Volume 25 • Issue 6


Publisher's Note: We are pleased to provide you with an eTOC for the latest issue of Canadian Journal of Infectious Diseases & Medical Microbiology.

A microbiological explanation for the obesity pandemic?
L Valiquette, S Sirard, K Laupland

That other EVD: Enterovirus-D68 – what’s it all about?
JL Robinson, S Suresh, BE Lee

Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study
S Shalhoub, L Wang, A Ching, S Husain, C Rotstein

Patients with neutropenia resulting from chemotherapy for hematological malignancies are at risk for considerable morbidity and mortality due to invasive fungal infections and should, thus, be treated with antifungal agents. Caspofungin has been one of the most common antifungal agents used for this purpose; its analogue micafungin may also be appropriate, but has not been tested as extensively. Accordingly, the authors of this article conducted a retrospective study to compare these two agents; the results contribute to the literature regarding the use of micafungin for the treatment of invasive fungal infections.


Triage and protocol recommendations for the parasitology laboratory based on an epidemiological investigation of parasite diagnostics in Ontario laboratories
A Maier, J Krolik, A Majury

Parasitic infections associated with gastroenteritis can cause considerable morbidity and mortality, and may be endemic or nonendemic in Ontario. Recently, there have been developments in laboratory protocols for identifying such parasites. The authors of this study used retrospective data from a single laboratory sector in Ontario to develop protocols for the diagnosis of parasitic infections, and also assessed risk factors associated with these infections.


CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults
M Hull, S Shafran, A Tseng, P Giguère, MB Klein, C Cooper, on behalf of The CIHR Canadian HIV Trials Network HIV/Hepatitis C Management and Treatment Guidelines Working Group

Treatment of HIV-hepatitis C virus (HCV)-coinfected individuals is considerably more complex than the treatment of monoinfected individuals, due to several factors including interactions among medications and accelerated progression of liver disease. Since the first Canadian guidelines for the treatment of HIV-HCV coinfected patients were published in the Winter 2013 issue of the Journal, several new medications that show considerable promise for the treatment of HCV have become available in Canada. Thus, the authors provide an update to the 2013 guidelines and include updated recommendations for treatment that incorporate these new medications.


A 71-year-old woman with recurrent falls and confusion
M Mehmood, ON Nadhem, FA Khasawneh

Aches and pains with a shocking rash
A Chacko, S Mahant, A Petrich, A Wadhwa

Therapeutic monitoring of triazoles: A needs assessment review and recommendations from a Canadian perspective
M Laverdiere, EJ Bow, C Rotstein, J Autmizguine, R Broady, G Garber, S Haider, T Hussaini, S Husain, P Ovetchkine, JT Seki, Y Théorêt

Therapeutic drug monitoring (TDM) is necessary for certain drugs to ensure that the levels are sufficient to be effective, but not so high as to cause adverse effects. This review summarizes the literature regarding TDM for newer-generation extended-spectrum triazoles, including when TDM may be necessary for each drug and why, and laboratory techniques used for the measurement of levels of these drugs. The document includes recommendations for the use of TDM for each triazole that is discussed.


The first case of locally acquired tick-borne Babesia microti infection in Canada
JMP Bullard, AN Ahsanuddin, AM Perry, LR Lindsay, M Iranpour, A Dibernardo, PG Van Caeseele

Infection with Babesia microti can cause severe illness, particularly among asplenic individuals. Blacklegged and Western blacklegged ticks (Ixodes scapularis and Ixodes pacificus, respectively) are the vector through which B microti is transmitted. The distribution of these ticks in Canada has increased over the past several years. In this article, the authors present the first case of babesiosis in Canada that was not diagnosed following travel to an area in which the disease is endemic.



Please take a moment to provide us with your feedback. It is only by working with readers, authors, society members and sponsors that this website will develop to meet the needs of everyone concerned.

Important Note: To ensure the receipt of the eTOC email please add CanadianJournalofInfectiousDiseasesAndMedicalMicrobiology@pulsus.com to your safe sender list.